ClinicalTrials.gg
Enrolling by invitationNCT07770035SOPHIEUpdated Aug 18, 2026

School-aged Outcomes Post Hypoxic Ischaemic Encephalopathy

An observational study in Hypoxic-Ischemic Encephalopathy, sponsored by University College Cork. Enrolling by invitation at 1 site in Ireland. Open to participants aged 5 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by University College Cork · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
196
Ages
5 Years to 12 Years
Sex
All
01

Study summary

Neonatal HIE increases the risk for cognitive impairments in childhood. Neonatal MRI brain scans are a strong predictor for outcome, however a normal scan has only a 35% sensitivity and 85% specificity for a normal outcome. This may be explained by variability in the brain's development over time in response to the initial insult.

This project will aim to develop a neonatal MRI machine learning algorithm that incorporates both initial injury and radiomic features associated with future brain development (based on school-age MRI) to predict school-age outcome. This will be achieved by conducting a case-control cohort study looking at School-age MRI and outcomes of children with a history of neonatal HIE.

Read the detailed description

The study will recruit children with a history of HIE in the newborn period (cases) and healthy children with an unremarkable newborn period (controls) born between January 2013-December 2020. During this period several prospective cohort studies of term infants ≥36 weeks at risk of HIE were conducted in Cork University Maternity Hospital (CUMH) neonatal intensive care unit (NICU).

Infants enrolled in these previous studies had neonatal data collected, in addition to detailed neurological assessments, neurophysiological monitoring, neonatal MRIs, and standardised neuro-developmental follow-up at two years of age using the Bayley Scale of Infant Development (BSID). These children were not followed after the BSID was performed. Approval for these studies was given by the Clinical Research Ethics Committee of the Cork Teaching Hospitals (CREC), and informed consent obtained. Cases for the proposed study will be identified from those who agreed on the original consent form to be contacted for future related research.

For control recruitment, the study will be advertised on social media, the INFANT website and in the Paediatric outpatient area in the adjacent Paediatric department. Healthy children aged between 5 and 12 years of age will be invited to contact the research team to be part of the control group. To be eligible, they must have been born at ≥ 36 weeks gestation, now attending mainstream school, did not have a diagnosis of HIE or have been admitted to the neonatal unit in the first 12 hours of birth. A new ethics submission for the current study was approved by the local CREC.

Sample Size: Taking the mean population IQ as 100 with a standard deviation of 15, we calculated that 98 cases will be needed to detect a 6-point difference in composite IQ with an alpha of 0.05 and a power of 80%. The same number of controls will be recruited, giving a total number of 196 participants. This sample is powered to show a meaningful difference in IQ between populations from which the predictive models are built. Regarding the radiomic analysis proposed there is very limited data in neonatal populations, but the sample size proposed would represent the largest neonatal radiomic study to-date, and would also be comparable to recent adult studies with similar proposed methodology.

Study Procedures:

If the parents/guardians agree to participate, written informed consent and age-appropriate assent will be obtained.

There will be two study visits. The first will involve performing the cognitive assessment, administration of questionnaires, and a short play therapy session to introduce the child to the MRI using a mock MRI scanner and video of the MRI department and scanner. The assessment will take a standardised format, taking approximately 1.5 hours in total and breaks will be provided as necessary.

The MRI will be performed at the second visit. The scanning protocol will be approximately 19 minutes in duration, with four key MRI sequences being performed. No sedation or anesthesia will be provided for the MRI. Qualitative and quantitative analysis of the MRI will be performed.

The goal of this project is to develop a predictive neonatal MRI biomarker algorithm that combines radiomic features associated with evolution of brain injury on School-age MRI scans, and qualitative neonatal MRI assessment, to predict School-age cognitive outcome following Neonatal HIE.

The specific objectives are

  1. To develop a Neonatal MRI machine learning model of radiomic features predictive of significant future evolutional changes evident on school-age MRI following HIE

    • Perform School-age MRI in both a large cohort of infants with HIE (with available neonatal MRI) and an age-matched control population (did not have neonatal MRI).
    • School-age MRI to be assessed for qualitative injury, and perform regional volumetric analysis.
    • Psychological assessment of cognitive function, executive function, and full-scale IQ in all grades of HIE (mild, moderate, and severe) and compare to an age-matched control population.
    • Correlation of School-age MRIs (Case and Control) with School age psychological outcome to identify key features associated with outcome.
    • In HIE cohort, following identification of key features predictive of cognitive outcome on School-age MRI (regions of interest[ROI]), to project these ROIs onto the Neonatal MRI to identify radiomic features predictive of evolution of brain imaging findings.
    • Develop machine learning algorithm of radiomic features on neonatal MRI predictive of significant school-age MRI changes
  2. To develop MRI Only predictive model for School-age Outcome: To develop predictive algorithm combining Neonatal MRI radiomic model developed (objective 1) and qualitative neonatal MRI findings, to predict School-age Psychological outcome.
  3. To develop MRI and Clinical model for School-age Outcome: To develop a predictive machine learning algorithm combining Clinical and sociodemographic factors, with our Neonatal MRI radiomic model, and qualitative neonatal MRI findings to predict School-age Psychological outcome.
02

Conditions studied

  • Hypoxic-Ischemic Encephalopathy

Keywords

  • HIE
  • neonatal encephalopathy
  • neurodevelopment
  • cognitive outcome
  • MRI
03

In context

Hypoxia-Ischemia, Brain

261 studies on the registry are indexed under Hypoxia-Ischemia, Brain; 95 are open to participants now.

This study's planned enrollment of 196 is above the median of 100 across 92 observational studies indexed under Hypoxia-Ischemia, Brain.

Browse Hypoxia-Ischemia, Brain studies →

Lead sponsor

University College Cork is the lead sponsor of 119 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Cases:

Potential participants will be identified from seven previous studies conducted in Cork University Maternity Hospital (CUMH), between January 2013-December 2019. Over this period, term infants ≥36 weeks considered at significant risk of HIE were recruited prospectively to these studies as soon as possible after delivery. Clinical data, blood biomarkers, MRI and EEG recordings were collected and stored in the INFANT databank using unique study numbers.

Controls:

Children aged between 4-12 years of age, who are attending general paediatric outpatients' clinics at Cork University Hospital (CUH) will be selected as potential participants for the control group.

Controls will be healthy children born at ≥ 36 weeks gestation now attending mainstream school who did not have a diagnosis of HIE at birth. To be eligible, they must not have been admitted to the neonatal unit in the first 12 hours after birth and have had a 5-minute Apgar score of ≥7.

Eligibility criteria

Cases:

Inclusion Criteria:

  • Known diagnosis of HIE of any grade and enrolled in one of seven studies carried out in CUMH and born between 01 JAN 2013 and 31 DEC 2020
  • Documented parental for their study data to be used in the future for related research and for them to be contacted again.

Exclusion Criteria:

  • Lack of parental consent for the original study and no permission to be contacted for future research.
  • Death prior to study initiation
  • Congenital malformation or genetic syndrome

Controls:

Inclusion Criteria:

  • Born at ≥ 36 weeks gestation
  • Attending mainstream primary school without a specific developmental diagnosis

Exclusion Criteria:

  • Diagnosis of perinatal asphyxia or HIE at birth
  • Admission to the neonatal unit within 12 hours of birth
  • Attending a paediatric clinic for a developmental concern
  • Congenital malformation or genetic syndrome
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
196 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hypoxic Ischaemic Encephalopathy (Case)

    Children aged 5-12 years old with HIE meeting study inclusion criteria

  • Age-Matched Control

    Healthy controls aged 5-12 years old, now attending mainstream school, who did not have HIE or were not admitted to the neonatal unit within 12 hours of birth.

06

What researchers measure

Primary outcomes

  1. Intelligence Quotient

    Kaufman Brief Intelligence Test Second Edition (KBIT-2) is a brief measure of verbal and nonverbal intelligence used with individuals aged from 4 to 90 years.

    Time frame: Visit 1 - Approx 1.5 hours, aged 5-12 years old

  2. Assessment of Exectuive Function

    Cambridge Neuropsychological Test Automated Battery (CANTAB) will be used to assess the following domains: Visual Memory- Delayed Match to Sample (DMS) Working memory- Spatial Working Memory Task (SWM), Spatial Span Task (SSP), Digit Span Task (DGS) Attention/processing speed- Reaction Time Task (RTI), Rapid Visual Processing Task (RVP), Motor Screening Task (MOT) Inhibitory control- Stop Signal Task (SST)

    Time frame: Visit 1 - Approx 1.5 hours, aged 5-12 years old

  3. Volumetric analysis of MRI brain

    Total and regional brain volumetric analysis

    Time frame: Visit 2 - 20 minute MRI scan, approximately 2-4 months after Visit 1

  4. Connectivity analysis of MRI brain

    Analysis of brain connectivity using diffusion tensor data and fransctional anisotopy imaging.

    Time frame: Visit 2 - 20 minute MRI scan, approximately 2-4 months after Visit 1

  5. MRI Machine Learning Model

    Using MRIs completed at school-age and neonatal data, extract radiomic features and ragions of interest (ROIs) to develop machine learning models to predict school-aged cognitive outcome.

    Time frame: Visit 2 - 20 minute MRI scan, approximately 2-4 months after Visit 1

Secondary outcomes

  1. Behavioural Profile

    Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire about 2-17 year olds, examining attributes across 4 scales: emotional symptoms (0-10), condict problems (0-10), hyperactivity/inattention (0-10) and peer relationship problems (0-10). These 4 scales contribute to the total difficulties score (0-40), with a higher socre indicting a higher level of difficulty. There is also a prosocial behaviour scale, which runs from 10-0; a higher socre on this scale indicates a more typical social profile, and is not included in the total difficulties score.

    Time frame: Visit 1 - Approx 1.5 hours, aged 5-12 years old

  2. Incidence of additional school supports

    Parents will complete a sociodemographic questionnaire which asks about school support, need for special needs assistant, and additonal diagnosis, e.g., attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), dyslexia, dyspraxia

    Time frame: Visit 1 - Approx 1.5 hours, aged 5-12 years old

  3. Socioeconomic Background

    Parental education and occupation

    Time frame: Visit 1 - Approx 1.5 hours, aged 5-12 years old

  4. Cognitively Stimulating Home Environment

    Adapted survey from Chew et al, 2024, examining measure of the home environment which can influence cognitive abilities

    Time frame: Visit 1 - Approx 1.5 hours, aged 5-12 years old

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — The datasets analysed during the current study will be available from the corresponding author on reasonable request.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07770035
Responsible party
Brian Walsh (Consultant Neonatologist, University College Cork) — Principal investigator
First posted
Aug 18, 2026
Start date
Mar 9, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 18, 2026

Study contacts

Brian H Walsh, PhD
principal investigator · University College Cork

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion